Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential. (Q39119297)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23892718%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

title

Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23892718%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

1 reference

ChEBI release 2020-05-28

1 reference

lymphoblastic leukemia

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23892718%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Alice Cani

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23892718%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Carolina Simioni

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23892718%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

James A. McCubrey

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23892718%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Silvano Capitani

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23892718%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

author name string

A M Martelli

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23892718%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

C Junghanss

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23892718%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

G Tabellini

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23892718%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

F Ricci

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23892718%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

P L Tazzari

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23892718%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

P Pagliaro

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23892718%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

publication date

29 July 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23892718%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23892718%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23892718%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23892718%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

page(s)

739-748

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23892718%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/leu.2013.226

6 March 2020

exact match

0 references

cites work

Advances in the molecular pathobiology of B-lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.226

The clinical relevance of chromosomal and genomic abnormalities in B-cell precursor acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.226

Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.226

Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.226

The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.226

Intracellular reactive oxygen species are essential for PI3K/Akt/mTOR-dependent IL-7-mediated viability of T-cell acute lymphoblastic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.226

Silencing of ETV6/RUNX1 abrogates PI3K/AKT/mTOR signaling and impairs reconstitution of leukemia in xenografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.226

mTOR and cancer: reason for dancing at the crossroads?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.226

mTOR-targeted therapy of cancer with rapamycin derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.226

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.226

Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.226

Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.226

Antiproliferative effect of rapamycin on human T-cell leukemia cell line Jurkat by cell cycle arrest and telomerase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.226

Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.226

Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.226

Updates of mTOR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.226

Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.226

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.226

Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.226

AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.226

Revealing the role of TEL/AML1 for leukemic cell survival by RNAi-mediated silencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.226

AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.226

The multikinase inhibitor Sorafenib displays significant antiproliferative effects and induces apoptosis via caspase 3, 7 and PARP in B- and T-lymphoblastic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.226

PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.226

The short form of RON is expressed in acute myeloid leukemia and sensitizes leukemic cells to cMET inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.226

Endogenous knockdown of survivin improves chemotherapeutic response in ALL models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.226

Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.226

Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.226

Differential requirements for c-Myc in chronic hematopoietic hyperplasia and acute hematopoietic malignancies in Pten-null mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.226

Bcl-2 down-regulation causes autophagy in a caspase-independent manner in human leukemic HL60 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.226

Autophagy promotes intracellular degradation of type I collagen induced by transforming growth factor (TGF)-β1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.226

The role of lipids in the control of autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.226

Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.226

The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung cancer in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.226

Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.226

MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.226

Next-generation Akt inhibitors provide greater specificity: effects on glucose metabolism in adipocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.226

Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.226

TORgeting oncogene addiction for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.226

Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.226

The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.226

Phosphorylated mTOR expression is associated with poor prognosis for patients with esophageal squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.226

Activation of Akt is associated with poor prognosis and chemotherapeutic resistance in pediatric B-precursor acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.226

Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.226

Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.226

Autophagy in aging, disease and death: the true identity of a cell death impostor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.226

RAD001 (Everolimus) induces autophagy in acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.226

Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.226

Dual targeting of the Akt/mTOR signaling pathway inhibits castration-resistant prostate cancer in a genetically engineered mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.226

The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.226

A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.226

Discovery of a regulatory motif that controls the exposure of specific upstream cyclin-dependent kinase sites that determine both conformation and growth suppressing activity of pRb

21 January 2018

1 reference

12 December 2020

Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma

1 reference

12 December 2020

Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies

1 reference

12 December 2020

Activation of mammalian target of rapamycin pathway confers adverse outcome in nonsmall cell lung carcinoma

1 reference

12 December 2020

A novel pre-B acute lymphoblastic leukemia cell line with chromosomal translocation between p16(INK4A)/p15(INK4B) tumor suppressor and immunoglobulin heavy chain genes: TGFbeta/IL-7 inhibitory signaling mechanism

1 reference

12 December 2020

Inactivation of retinoblastoma protein in uveal melanoma by phosphorylation of sites in the COOH-terminal region.

1 reference

12 December 2020

Cytogenetics in pre-B and B-cell acute lymphoblastic leukemia: a study of 208 patients diagnosed between 1981 and 2008

1 reference

12 December 2020